OKYO Pharma (NASDAQ: OKYO) showcases urcosimod NCP data at Eyecelerator and ARVO
Rhea-AI Filing Summary
OKYO Pharma is highlighting its eye disease program through upcoming scientific meetings and recent clinical data. The CEO will present at Eyecelerator on May 1, 2026, and the Chief Scientific Officer will present Phase 2 data at the ARVO Annual Meeting in Denver in early May.
The company’s lead drug, urcosimod, is an investigational therapy for neuropathic corneal pain (NCP) and inflammatory eye diseases. It is the first therapy to receive an IND specifically for NCP and has Fast Track designation from the U.S. FDA. OKYO reports clinically meaningful pain reduction and quality-of-life improvement in an 18-patient randomized, placebo-controlled, double-masked Phase 2 NCP trial, and statistically significant results in an earlier 240-patient Phase 2 dry eye disease trial. OKYO plans to start a 150-patient Phase 2b/3 multiple-dose NCP study in the first half of the year.
Positive
- None.
Negative
- None.
Insights
OKYO is advancing urcosimod for neuropathic corneal pain with supportive Phase 2 data and upcoming scientific visibility.
OKYO Pharma emphasizes its lead candidate urcosimod for neuropathic corneal pain (NCP), a debilitating eye condition with no FDA-approved therapies. The drug has an IND specifically for NCP and holds FDA Fast Track designation, underscoring regulatory recognition of the unmet need.
The company cites a randomized, placebo-controlled, double-masked Phase 2 NCP study in 18 patients showing clinically meaningful pain and quality-of-life improvement, plus an earlier 240-patient Phase 2 trial in dry eye disease with statistically significant endpoints. A planned 150-patient Phase 2b/3 NCP study could provide more robust efficacy and safety data once underway.
Presentations at Eyecelerator on May 1, 2026 and at the ARVO Annual Meeting in early May 2026 will share these findings with clinicians and researchers. Future disclosures on the design, conduct, and results of the planned Phase 2b/3 trial will shape understanding of urcosimod’s potential in NCP.
Key Figures
Key Terms
neuropathic corneal pain (NCP) medical
Fast Track designation regulatory
Investigational New Drug (IND) regulatory
Phase 2b/3 multiple-dose study medical
G-protein coupled receptor medical
double-masked, placebo-controlled trial medical
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
April 2026
Commission File Number: 001-41386
OKYO Pharma LTD
(Exact Name of Registrant as Specified in Its Charter)
9th Floor
107 Cheapside
London
EC2V 6DN
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On April 29, 2026, OKYO Pharma LTD (the “Company”) issued this 6K announcing CEO presentation at Eyecelerator and leadership participation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Denver, Colorado.
The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-293145)
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| OKYO Pharma LTD | ||
| Date: April 29, 2026 | By: | /s/ Keeren Shah |
| Name: | Keeren Shah | |
| Title: | Chief Financial Officer | |
| 3 |
EXHIBIT INDEX
| Exhibit No. | Description | |
| 99.1 | News Announcement, dated April 29, 2026 |
| 4 |
Exhibit 99.1
OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May
| ● | Robert J. Dempsey, MBA, Chief Executive Officer, to present at Eyecelerator | |
| ● | Raj Patil, PhD, Chief Scientific Officer, to present at ARVO |
London and New York, NY, April 29, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced CEO presentation at Eyecelerator and leadership participation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Denver, Colorado.
Upcoming Scientific Conferences:
Eyecelerator: May 1, 2026
Denver, Colorado
Presentation Title: Addressing Unmet Needs in Corneal and Anterior Segment Diseases
Presentation Date/Time: Friday May 1, 2026, 2:10-2:15 PM MDT
Breakout: Anterior Segment, Room 401
Presenter: Robert J. Dempsey, Chief Executive Officer at OKYO Pharma
Moderators: Julie Schallhorn, MD, MS; Kuldev Singh, MD
ARVO Annual Meeting: May 3-7, 2026
Denver, Colorado
Presentation Title: First-in-Human Study of Urcosimod to Treat Neuropathic Corneal Pain (NCP) Shows Clinically Meaningful Pain Reduction and Quality-of-Life Improvement in NCP Patients
Presentation Date/Time: Tuesday May 5, 2026, 3:30 PM to 5:15 PM MDT
Poster Presentation/Board: 3461/0044
Session Title: Corneal Neuropathy and Ocular Pain
Session Number: Number 366
Presenter: Raj Patil, PhD, Chief Scientific Officer at OKYO Pharma
ARVO’s Annual Meeting is the premier global gathering for eye and vision scientists, students, and those in affiliated fields to share the latest research findings and collaborate on innovative solutions.
Urcosimod is the first investigational therapy to receive an IND specifically for the treatment of neuropathic corneal pain and has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).
About Neuropathic Corneal Pain (NCP)
Neuropathic corneal pain (NCP) is a chronic, often debilitating condition characterized by severe pain and sensitivity of the eyes, and in some cases the face or head. It is thought to result from damage or dysfunction of corneal sensory nerves, often in combination with inflammatory processes, and may occur in patients with a range of underlying ophthalmic conditions. There are currently no FDA-approved therapies specifically for NCP, resulting in patients being treated with limited or no success using various topical and systemic medications in an off-label manner.
About Urcosimod (formerly called OK-101)
Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in a mouse model of dry eye disease and in a neuropathic corneal pain mouse model, respectively. OKYO recently announced positive data on NCP pain reduction in a randomized, placebo-controlled, double-masked Phase 2 trial involving 18 neuropathic corneal pain patients. Urcosimod showed clear statistical significance in multiple endpoints in an earlier 240-patient Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease.
About OKYO Pharma
OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and inflammatory eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in patients with NCP and plans to initiate a 150-patient Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year.
For further information, please visit www.okyopharma.com.
For further inquiries:
OKYO Pharma Ltd
Paul Spencer
Business Development, and Investor Relations
+44 (0) 207 495 2379
Email: info@okyopharma.com